Information on late onset liver complications after childhood cancer is scarce. To ensure an appropriate follow-up of childhood cancer survivors and reducing late liver complications, the need for comprehensive and accurate information is presented. We evaluate the risk of liver diseases in a large childhood cancer survivor cohort. We included all 1-year survivors of childhood cancer treated in the five Nordic countries. A Cox proportional hazards model was used to estimate hospitalisation rate (hazard) ratios (HRs) for each liver outcome according to type of cancer. We used the risk among survivors of central nervous system tumour as internal reference. With a median follow-up time of 10 years, 659 (2%) survivors had been hospitalised at least once for a liver disease. The risk for hospitalisation for any liver disease was high after hepatic tumour (HR 5 6.9) and leukaemia (HR 5 1.7). The Danish sub-cohort of leukaemia treated with haematopoietic stem cell transplantation had a substantially higher risk for hospitalisation for all liver diseases combined (HR 5 3.8). Viral hepatitis accounted for 286 of 659 hospitalisations corresponding to 43% of all survivors hospitalised for liver disease. The 20-year cumulative risk of viral hepatitis was 1.8% for survivors diagnosed with cancer before 1990 but only 0.3% for those diagnosed after 1990. The risk of liver disease was low but significantly increased among survivors of hepatic tumours and leukaemia. Further studies with focus on the different treatment modalities are needed to further strengthen the prevention of treatment-induced late liver complications.
Introduction
Childhood cancer treatment has improved greatly over the past decades with 5-year survival rates now exceeding 80% in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). 1 This has resulted in a steeply increasing number of survivors who are, unfortunately, under increased risk for a broad range of late effects from cancer therapy, including damage to the liver. 2, 3 Acute liver toxicity has been reported in close connection to cancer therapy or shortly after. 4, 5 It has been suggested that childhood cancer survivors are at risk of late liver complications when receiving chemotherapy, in particular methotrexate, 6-mercaptopurine, 6-thioguanine, busulphan and dactinomycin; haematopoietic stem cell transplantation (HSCT), radiotherapy involving the liver including total body irradiation, or hepatectomy. 6 However, it remains not clear what specific mechanism which causes long-term liver complications and only a few large cohort studies have investigated long-term liver complications in survivors of childhood cancer. The US Childhood Cancer Survivor Study (CCSS) found that childhood cancer survivors have an overall twofold increased risk for liver disease compared to siblings and the risk was associated with older age at cancer diagnosis, alkylating agent exposure, anthracycline use, abdominal surgery and total body irradiation (TBI).
To ensure an appropriate follow-up of childhood cancer survivors and to reduce late liver complications, comprehensive and accurate information is essential. By use of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study, which is based on data from the five national Nordic cancer registries and a long-term follow-up in the national hospital registers, we present a detailed overview of the relative and absolute risks for liver diseases serious enough to require in-patient treatment and care. To further elaborate the results we also wanted to assess the possible impact of HSCT on liver toxicity as this has been suggested to cause hepatic dysfunction.
Methods
ALiCCS is a nation-wide and population-based cohort study, investigating late effects after treatment for childhood cancer (www.aliccs.org). 8 
Childhood cancer cohort
In the five Nordic cancer registries, we identified 43,909 individuals in whom cancer was diagnosed before the age of 20 years between the start of the registries in the 1940 sec and 50 sec (earliest in Denmark in 1943), and December 31, 2008. Only individuals alive or born after the date on which centralised registration of residents was operational with all required variables in each of the countries (Iceland 1955; Norway 1960; Denmark and Sweden 1968 and Finland 1971) were included in the cohort, all with diagnostic information and date of diagnosis. Each of the cancer registries is nationwide, and a cancer diagnosis is reported from several sources ensuring virtually 100% coverage. 9 Cancers were grouped into 12 main diagnostic groups according to the International Classification Scheme for Childhood Cancer (ICCC). 10 Since the start of the central civil registration systems in the Nordic countries, all residents have been assigned a unique personal identification number, which allows accurate linkage of information between registries.
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Before linkage of study subjects to the respective national hospital registers (see below), we excluded those in whom more than one primary cancer was diagnosed before the age of 20 years (305 patients); those who had died or emigrated before the start of the national hospital register (7,251 patients) and those who had died or emigrated during the first year after the date of cancer diagnosis (3,193 patients) , leaving 33,160 one-year survivors for further linkage with outcome data.
Hospitalisations for liver diseases
Information on hospitalisations in the five countries was obtained from the nationwide hospital registers. Each hospitalisation initiates a record, which includes the personal identification number of the patient, dates of admission and discharge, a primary discharge diagnosis and a varying number of supplementary diagnoses coded according to the International Classification of Diseases (ICD), 7th to 10th revisions (ICD-7 to ICD-10). Diagnostic categories of ICD-7 to ICD-9 were adapted to the categories of ICD-10 (Table S1 ).
For each 1-year survivor of childhood cancer we identified all in-patients hospitalisations with a primary or supplementary discharge diagnosis of the liver sections of the ICD. We excluded survivors, who had been hospitalised for a liver disease prior to the date of diagnosis of childhood cancer (124 patients). We also excluded survivors diagnosed with a chromosomal abnormality (ICD-10 codes Q90-99; 197 patients) since these conditions may potentially confound any causal associations between cancer treatment and chronic disorder, leaving 32,839 one-year survivors for analyses ( Table 1) .
Survivors of childhood cancer in the Danish sub-cohort who underwent HSCT were identified using a dedicated clinical database located at the only centre in the country performing HSCT. Information on HSCT was registered for 294 of 1,517 Danish patients treated for leukaemia. Information on HSCT was only available for the Danish sub-cohort of childhood leukaemia survivors.
Statistical analysis
The follow-up period for liver disease in the hospital registers started 1 year after the date of cancer diagnosis, or at the start of the national hospital register, whichever occurred latest. Follow-up ended on the date of a liver disease, date of death, the date of emigration, date of second primary cancer or end of study (Denmark: October 31, 2010; Finland: December 31, 2012; Iceland: December 31, 2008; Norway: December 31, 2010; Sweden: December 31, 2009), whichever occurred first. If survivors had more than one hospitalisation for a specific diagnostic category of liver disease, only the first record was retained as this was presumed to be the best proxy for date of diagnosis.
We applied a Cox proportional hazards model to estimate the hospitalisation rate (hazard) ratios (HRs) and associated 95% confidence intervals (95% CIs) for a first-time What's new? Battling childhood cancer takes a toll on the body that extends well into adulthood. Here, the authors investigated the likelihood of liver disease in the wake of chemotherapy. Using data from five Nordic national cancer registries, the authors compared the rates of hospitalisation for liver disease among survivors of different cancers. Those who fought off CNS tumours were least likely to face liver disease later, while patients who had been treated for liver cancer or leukemia, particularly those who'd received hematopoietic stem cell transplants, had the greatest chance of subsequent liver problems.
hospitalisation for all liver disease combined and for each diagnostic category of liver disease separately. Analyses were stratified according to the main diagnostic types of childhood cancer with time since cancer diagnosis as the underlying time scale and censoring for death, emigration, second malignancy or end of follow-up. We used the group of patients with central nervous system (CNS) tumour as internal reference as this group was considered a large reference group and assumed to have the lowest excess risk for liver diseases of the largest groups of survivors within the childhood cancer classification system. The analyses were adjusted for sex and country by stratification in the Cox model, allowing for any differences in the underlying hospitalisation intensities. Age at cancer diagnosis was included as a covariate in 5-year intervals.
Cumulative risks for hospitalisation due to viral hepatitis was estimated as a function of attained age using a competing risk framework. 12 In this analysis, we only included those who were diagnosed with cancer 1 year prior to or after the start of the national hospital registers.
In the subset of Danish survivors of leukaemia, HSCT was grouped as a dichotomous variable (yes/no).
The statistical software R version 2.12.0 and the packages Survival and Design were used for all statistical analyses.
Data on cohort members were received and analysed without use of personal identifiers in accordance with Nordic regulations. The study was approved either by the National Bioethics Committees, Data Protection Authorities or the national institute for health and welfare in the respective countries Results Table 1 summarises key characteristics for the 32,839 oneyear survivors of childhood cancer available for risk analysis. The median follow-up time of survivors in the national hospital registries was 10 years (range 0-42); 15,307 (47%) were females, 12,482 (38%) survivors were from Sweden, and 17,220 (52%) were diagnosed with cancer in the most recent period, 1990-2008. During follow-up, 659 (2.0%) were hospitalised for a liver disease (Table 2) .
Results for all types of liver disease combined
Compared to survivors of CNS tumours, survivors of hepatic tumours were at highest overall risk for being hospitalised for a disease of the liver (HR 5 6.9; 95% CI 4.1-12) followed by survivors of leukaemia (HR 5 1.7; 95% CI 1.4-2.2) ( Table 2) .
Results for a selected number of liver diseases separately Table 2 gives the risk for hospitalisation for specific liver diseases by main diagnostic type of childhood cancer, again with the use of the risk among survivors of CNS tumours as reference level. Overall, 43% of survivors hospitalised for liver diseases had been hospitalised for viral hepatitis; the risk was slightly-tomoderately increased in survivors of hepatic tumours (HR 5 1.7), and leukaemia (HR 5 1.2) when compared to the Cancer Epidemiology risk in survivors of CNS tumours. However, the elevations were not statistically significant. Figure 1 illustrates the cumulative incidence of hospitalisation for viral hepatitis from start of follow-up for all 1-year survivors of childhood cancer diagnosed in the period prior to and after 1990, respectively; some 20 years after, the cumulative risks were 1.8% and 0.3%, respectively.
The risk of hospitalisation for liver cirrhosis was significantly increased in survivors of leukaemia.
The risk of hospitalisation for hepatitis with abscess formation (suppurative hepatitis) was extraordinarily high for survivors of hepatic tumours, and leukaemia, while the risk of hospitalisation for acute and subacute necrosis of the liver was markedly increased for survivors of hepatic tumours (HR 5 49), neuroblastoma (HR 5 7.1) and leukaemia (HR 5 5.7).
Survivors of hepatic tumours were also at markedly increased risk for certain other liver diseases, including oesophageal varices, and alcoholic liver disease (Table 2) . Survivors of renal tumours stood out as the only main diagnostic group of childhood cancer with a significantly increased risk of hospitalisation for portal hypertension with 12 cases notified out of 1,405 patients ( Table 2 ).
Haematopoietic stem cell transplantation
Danish survivors of leukaemia who were treated with HSCT had in general substantially higher risks for hospitalisation for all liver diseases combined (HR 5 3.8; 95% CI 1.7-8.2) as well as for several of the specific categories of liver disease, separately, compared to the risk in survivors of leukaemia exclusively treated with chemotherapy, Table 3 .
Discussion
Survival of children and adolescents diagnosed with cancer has improved tremendously over the past decades. Therefore, we need to strengthen our focus on the potential late complications to the cancer and its treatment. This populationbased cohort study was conducted to evaluate the potential risk of adverse hepatic outcomes in a large childhood cancer survivor cohort. We found the highest overall risks for liver disease in survivors treated for hepatic tumour and leukaemia. Whether the risk of hepatic adverse events correlates with the treatment with anthracyclines remains not clear. 7, 13 A systematic review of 20 cohort studies investigating hepatic Table 3 . Cox regression analysis with hazard ratios (HRs) and 95% confidence intervals (95% CIs) of hospitalisation for any liver disease among 294 leukaemia patient treated with HSCT in Denmark using the risk among 1223 Danish leukaemia patients treated with chemotherapy alone as reference late adverse effects after antineoplastic treatment for childhood cancer is inconclusive. 6 High cumulated doses of anthracyclines are used in acute myeloid leukaemia (AML) but liver diseases are uncommon in non-transplanted patients.
14 Some studies have suggested that the use of methotrexate induces mild structural changes of the liver that may lead to fibrosis/cirrhosis, although it rarely causes end-stage liver disease. 5, 15 It has been shown that both a high body mass index (BMI) and alcohol intake >14 units per week among survivors correlates with the risk of hepatic complications, similarly to the relationship in the general population. 13, 16, 17 These exposures could partially explain the increased risk of hepatic complications in survivors in our study but we were not able to examine this further due to lack of treatment information and information on lifestyle factors. Patients with acute lymphoblastic leukaemia are treated with prolonged 6-mercaptopurine and methotrexate causing acute liver toxicity but seldom chronic abnormalities. 18 Overall, 286 survivors out of the 32,839 one-year survivors of childhood cancer had been hospitalised with viral hepatitis and three of them had also been hospitalised for cirrhosis of the liver (data not shown). The risk for viral hepatitis was highest among survivors of hepatic tumour and leukaemia compared to the risk of survivors of CNS tumours; however these results were not statistically significant. In the Nordic countries blood products have been heat treated since the late 1980 sec and screened for hepatitis B virus and hepatitis C virus since the 1990 sec and therefore, the incidence of transfusion acquired viral hepatitis should be minimal. However, we did see elevated risks of viral hepatitis among childhood cancer survivors diagnosed before as well as after 1990, with cumulative incidences 20 years after cancer diagnosis of 1.8% and 0.3%, respectively. Whether the risk of viral hepatitis is due to accidental infection in relation to blood transfusion or to nosocomial infection is unknown. Our results emphasise that although a certain risk of viral hepatitis remains, the actual number of survivors affected is low indicating that the screening of blood products in the Nordic countries has lowered the risk markedly. However, accidental and nosocomial infection do occur, and awareness of this problem remains highly relevant. 19, 20 We saw an increased risk of being hospitalised for portal hypertension in survivors of Wilms tumour compared to the risk in survivors of other tumours. Similarly, Warwick et al. found survivors of Wilms tumour to be at increased risk of portal hypertension with a cumulative risk of 0.7% and 0.1% for right-sided and left-sided tumours, respectively, 6 years after cancer diagnosis. 21 They found an association between radiation exposure to the liver (>15 Gy) and risk of portal hypertension which may also be the explanation for the increased risks for portal hypertension seen in our Nordic study. All patients in the study by Warwick had received actinomycin-D (ACD), so they were not able to further evaluate the role of that treatment in regard to late liver damage. Another study found an increased risk of veno-occlusive disease (VOD) in patients treated with ACD, a risk which was higher when ACD was administrated as a single dose of 45 mg/kg compared to repeated dosing of 15 mg/kg. 22 We found a very high risk of being hospitalised for oesophageal varices in survivors of hepatic tumours. Oesophageal varices are most often a result from portal hypertension or liver cirrhosis. Many patients with liver cirrhosis will develop oesophageal varices over time. Despite improved treatment for oesophageal varices, the mortality still remains high. 23 An important clinical finding in our study was the increased risk of alcoholic liver disease in survivors of hepatic tumours. Alcoholic liver disease can cause cirrhosis of the liver. 24 The prognosis for patients diagnosed with cirrhosis of the liver is poor and the condition is very severe. 25 For this reason, early recognition for survivors at risk of cirrhosis of the liver is crucial. Though liver biopsy is the gold standard for diagnosing liver damage this would not be reasonable to perform regularly due to the invasive type of test. 13 Guidelines for survivors at risk of liver damage are important to minimise the further risk of injury. Education includes information on reduced alcohol consumption, and avoidance of obesity. 15 In the Danish sub-cohort, we were able to conduct an analysis of the risk for hospitalisation for liver diseases in survivors of leukaemia stratified by treatment with HSCT. We found that survivors of leukaemia treated with HSCT were at higher risk of any liver disease compared to survivors of leukaemia treated with chemotherapy alone. Subsequent liver disease in childhood leukaemia survivors treated with HSCT could be the result of a chronic graft-versus-host disease (GvHD), a chronic viral hepatitis, or sinusoidal obstruction disease (SOS) of the liver, previously known as VOD. [26] [27] [28] Their findings suggest that Nordic cancer patients who underwent HSCT could be at risk of GvHD, chronic viral hepatitis, and VOD and ultimately at higher risk of liver diseases. Reports have also found radiotherapy to be an important risk factor for hepatic adverse events. 7, 13 A large proportion of patients undergoing HSCT are exposed to TBI. This could explain the considerable difference in risk of hospitalisation of hepatic outcomes seen in our study. Liver complications could also be caused by transfusion-related haemochromatosis. Iron overload due to multiple transfusions is common in long-term survivors. 29 Despite significant iron overload after multiple transfusions in patients without HSCT it is often without signs of liver damage.
14 Iron overload can increase the risk of infections, VOD and hepatic dysfunction. 30 This Nordic population-based cohort study was conducted to evaluate the long-term risk of liver diseases by type of childhood cancer and -for survivors of leukaemia also by use of HSCT. With the population-based design and complete follow-up of survivors, we were able to eliminate the risk of selection bias. Our results should be interpreted in the context of certain limitations. Our study is limited by the general lack of treatment information in the individual cancer patient. Information on the use of alcohol and other medicaments as potential confounders were not available wherefore we were not able to take this into account in our analyses. Furthermore, information from the national hospital registries is not validated in details so a certain degree of misclassification cannot be ruled out if the diagnosis is registered wrongly or even a wrong diagnosis. However, Vestberg et al. estimated the validity for patients registered with a diagnosis of liver cirrhosis in the hospital discharge registry. They found an accuracy of 85% for liver cirrhosis. 31 We do not have information from general practitioners or out-patient visits in our study. Thus, if a patient is not hospitalised for a liver disease we do not know the full extent of incident cases of liver disease. Moreover, analyses performed to evaluate the risk of viral hepatitis were done without further classification of the different types of hepatitis.
We cannot rule out the potential multiple comparisons as a limitation of our study and might occur as we examined twelve different cancer types against eleven liver diseases. This should be taken into account when interpreting our results.
In conclusion, we found that survivors of leukaemia and hepatic tumour were at higher risk for all types of liver disease combined, compared to the risk in survivors of CNS tumours. Moreover, leukaemia patients treated with HSCT were at higher risk for being hospitalised for all types of liver disease combined, compared to the risk in leukaemia patients treated with chemotherapy alone. Furthermore, the risk for hospitalisation for viral hepatitis has been decreasing over time which demonstrates that the establishment of appropriate interventions works. Future studies with focus on the specific treatment modalities for childhood cancer are needed to further strengthen the prevention of treatment-induced liver diseases keeping in mind that late liver complications may change over time as a result of changes in the different treatment regimens. Future follow-up of childhood cancer survivors is essential to provide risk-based health screening and to provide preventive counselling for childhood cancer survivors to reduce morbidity and improve quality of life.
